Summary by Moomoo AI
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED ON 28 MARCH 2024 THAT ITS HOLDING COMPANY FUSTAR PHARMACEUTICAL INDUSTRY DEVELOPMENT CO., LTD. (“FUSTAR PHARMACEUTICALS”) HAS SECURED A RMB 9,000 MILLION LIQUID CAPITAL LOAN FILED BY THE INDUSTRIAL AND COMMERCIAL BANK OF CHINA WITH A GUARANTEE OF LIABILITY GUARANTEE FOR ITS HOLDING COMPANY FUSTAR PHARMACEUTICALS INDUSTRY DEVELOPMENT CO., LTD. (“FUSTAR PHARMACEUTICALS INDUSTRY”)。 The guarantee is within the range of a concern guarantee of not more than RMB33.3 billion as approved at the 2022 Annual General Meeting of Fustar Pharmaceuticals. As of the announcement date, including this guarantee, Fustar Pharmaceutical Group's actual external guarantee amount was approximately RMB86.26 billion, representing approximately 58.15% of the net assets of listed company shareholders audited at the end of 2023. FUSTAR PHARMACEUTICAL INDUSTRY WAS ESTABLISHED IN 2001 AS A WHOLLY OWNED SUBSIDIARY OF FUSTAR PHARMACEUTICALS. ITS MAIN ACTIVITIES INCLUDE PHARMACEUTICAL WHOLESALING, MANUFACTURING, TECHNICAL SERVICES, ETC. IN 2023, FUSTAR PHARMACEUTICALS INDUSTRY ACHIEVED OPERATING REVENUE OF RMB11.81 MILLION AND NET PROFIT OF NEGATIVE RMB4.65 MILLION.